Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

被引：58
|
作者：
Merino, Margret [1 ,3 ]
Kasamon, Yvette [1 ]
Theoret, Marc [1 ,2 ]
Pazdur, Richard [1 ,2 ]
Kluetz, Paul [1 ,2 ]
Gormley, Nicole [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[2] US FDA, Oncol Ctr Excellence, Silver Spring, MD USA
[3] White Oak 22 Room 2317,10903 New Hampshire Ave, Silver Spring, MD 20993 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 15期
关键词：
NONPLATINUM CHEMOTHERAPY; MULTIPLE-MYELOMA; CELL CARCINOMA; DOUBLE-BLIND; RECURRENT; OLAPARIB; PLACEBO; SOLO3;
D O I：
10.1200/JCO.23.00225
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2706 / +
页数：8
相关论文
共 50 条
  • [1] Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Guo, Siyuan
    Godolphin, Peter
    Hussain, Maha
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael A.
    Smith, Matthew R.
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nick
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09)
  • [2] Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
    Solomon, B. J.
    Loong, H. H.
    Summers, Y.
    Thomas, Z. M.
    French, P.
    Lin, B. K.
    Sashegyi, A.
    Wolf, J.
    Yang, J. C-H
    Drilon, A.
    ESMO OPEN, 2022, 7 (02)
  • [3] Progression-Free Survival Gaining on Overall Survival as a Gold Standard and Accelerating Drug Development
    Lebwohl, David
    Kay, Andrea
    Berg, William
    Baladi, Jean Francois
    Zheng, Ji
    CANCER JOURNAL, 2009, 15 (05) : 386 - 394
  • [4] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2012, 14 (06) : 483 - 485
  • [5] Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates
    Lipton, Allan
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) : 749 - 762
  • [6] Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
    Hess, Lisa M.
    Brnabic, Alan
    Mason, Oksana
    Lee, Pablo
    Barker, Scott
    JOURNAL OF CANCER, 2019, 10 (16): : 3717 - 3727
  • [7] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
    Susana Banerjee
    Stan Kaye
    Current Oncology Reports, 2012, 14 : 483 - 485
  • [8] Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    CANCERS, 2021, 13 (01) : 1 - 14
  • [9] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05) : 345 - +
  • [10] The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma
    Kirkizlar, Tugcan Alp
    Kirkizlar, Onur
    Soyluoglu, Selin
    Umit, Elif Gulsum
    Ustun, Funda
    Demir, Ahmet Muzaffer
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (05): : 353 - 359
12345